# ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML

> **NCT06463327** · PHASE1 · NOT_YET_RECRUITING · sponsor: **TC Biopharm** · enrollment: 69 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** TCB008

## Key facts

- **NCT ID:** NCT06463327
- **Lead sponsor:** TC Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463327, "ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06463327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*